Komori
COSMOS Pharmaceutical (3349) · InitiativeRestated

Reviewing the Rationale for Cross-Shareholdings and Selling Holdings

First written in FY2019. 4 of 6 entries say "Restated". Latest entry: FY2026.

6entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2023AdvancedFY20242019: 120192020: 020202021: 120212022: 120222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Review of the Economic Rationale for Holding Policy-Oriented SharesA theme 1248 companies write about · 1 as a headwind · 663 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1252 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    For cross-shareholdings, the Company continues its annual review by the Board of Directors and its policy of selling holdings with little economic rationale. It states that no holdings experienced either an increase or decrease in the number of shares during the fiscal year.
  2. FY2024AdvancedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    For cross-shareholdings, the Company continued its existing review and sale policy and sold 1 non-listed holding during the fiscal year.
  3. FY2023RestatedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    For cross-shareholdings, the Company continues its annual review by the Board of Directors and its policy of selling holdings with little economic rationale.
  4. FY2022RestatedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    For cross-shareholdings, the Company continues its annual review by the Board of Directors and its policy of selling holdings with little economic rationale.
  5. FY2021RestatedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    For cross-shareholdings, the Company continues its annual review by the Board of Directors and its policy of selling holdings with little economic rationale.
  6. FY2019First statedAnnual report

    「For shares held for purposes other than pure investment, the Board of Directors reviews each year whether continued ownership is appropriate, including whether conflicts of interest exist. Taking into account the cost of capital and other factors, we will sell shares that are judged to have little significance or economic rationale, while considering market conditions and other factors.」

    The company has established a policy of annually reviewing the significance and economic rationale of cross-shareholdings at Board meetings and selling holdings with insufficient rationale.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reviewing the Rationale for Cross-Shareholdings and Selling Holdings | COSMOS Pharmaceutical Corporation (3349) | Komori